BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 38486347)

  • 21. Update on dermatomyositis.
    Tanboon J; Nishino I
    Curr Opin Neurol; 2022 Oct; 35(5):611-621. PubMed ID: 35942671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.
    Muro Y; Sugiura K; Akiyama M
    Clin Rev Allergy Immunol; 2016 Dec; 51(3):293-302. PubMed ID: 26100618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on myositis-specific and myositis-associated autoantibodies.
    Targoff IN
    Curr Opin Rheumatol; 2000 Nov; 12(6):475-81. PubMed ID: 11092195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
    Hirakata M
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Dec; 30(6):444-54. PubMed ID: 18174673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies in polymyositis and dermatomyositis.
    Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A
    Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral immunity in polymyositis/dermatomyositis.
    Targoff IN
    J Invest Dermatol; 1993 Jan; 100(1):116S-123S. PubMed ID: 8423380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Mi-2 antibodies.
    Ghirardello A; Zampieri S; Iaccarino L; Tarricone E; Bendo R; Gambari PF; Doria A
    Autoimmunity; 2005 Feb; 38(1):79-83. PubMed ID: 15966133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myositis-specific autoantibodies].
    Fujimoto M
    Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myositis specific autoantibodies.
    Targoff IN
    Curr Rheumatol Rep; 2006 Jun; 8(3):196-203. PubMed ID: 16901077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
    Marzęcka M; Niemczyk A; Rudnicka L
    Clin Rev Allergy Immunol; 2022 Oct; 63(2):289-296. PubMed ID: 35147864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Myositis-specific autoantibodies].
    Gran JT; Molberg Ø; Dobloug GC; Andersson H; Taraldsrud E; Scheie D
    Tidsskr Nor Laegeforen; 2009 Aug; 129(16):1631-4. PubMed ID: 19721478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
    Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
    Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dermatomyositis: new antibody, new classification].
    Bolko L; Gitiaux C; Allenbach Y
    Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy.
    Richards M; García-De La Torre I; González-Bello YC; Vázquez-Del Mercado M; Andrade-Ortega L; Medrano-Ramírez G; Navarro-Zarza JE; Maradiaga-Ceceña M; Loyo E; Rojo-Mejía A; Gómez G; Seaman A; Fritzler MJ; Koenig M; Mahler M
    Rheumatology (Oxford); 2019 Sep; 58(9):1655-1661. PubMed ID: 30938432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Where are we moving in the classification of idiopathic inflammatory myopathies?
    Tanboon J; Uruha A; Stenzel W; Nishino I
    Curr Opin Neurol; 2020 Oct; 33(5):590-603. PubMed ID: 32852298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
    Wolstencroft PW; Fiorentino DF
    Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent findings in dermatomyositis-specific autoantibodies].
    Fujimoto M
    Rinsho Shinkeigaku; 2014; 54(12):1110-2. PubMed ID: 25672722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Mi-2 antibody-positive dermatomyositis following Spirulina intake.
    Kuzumi A; Yoshizaki A; Kawanabe R; Sato S
    Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38486347
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
    He L
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.